science
Latham & Watkins Advises on ADARx Pharmaceuticals’ Upsized US$446.3 Million Initial Public Offering
ADARx Pharmaceuticals, Inc., a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, has announced the pricing... The post Latham & Watkins Advises on ADARx Pharmaceuticals’ Upsized US$446.3 Million Initial Public Offering appeared first on Legal Desire Media and Insights .
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Abolis launches MINE to turn microbial data into industrial action
Indianpharmapost
ASMS & Huwel Lifesciences step up push to take Cubo RT-PCR platform across India
Indianpharmapost
Steering the biotech bus India's way
The New Indian Express
A Cosmic “Shrimp” With A Hidden Secret: NASA Reveals The Strange Motion Behind This Nebula
The Daily Galaxy
EVolve Conclave: Leaders discuss scaling electric mobility in India
Asianet Newsable